| 供应商 | 上海联迈生物工程有限公司 |
| 数量 | 大量 |
| 靶点 | 详见说明书 |
| 级别 | 1 |
| 目录编号 | LM-0091R-FITC |
| 克隆性 | 多克隆 |
| 抗原来源 | Rabbit |
| 保质期 | 1年 |
| 抗体英文名 | Anti-CA125/FITC |
| 抗体名 | Anti-CA125/FITC |
| 标记物 | FITC标记 |
| 宿主 | Human |
| 适应物种 | Human |
| 免疫原 | 详见说明书 |
| 亚型 | IGg |
| 形态 | 粉末、液体、冻干粉 |
| 应用范围 | IF=1:50-200 |
| 浓度 | 1mg/ml |
| 保存条件 | -20 °C |
| 规格 | 100ul |
| 英文名称 | Anti-CA125/FITC |
| 中文名称 | FITC标记的卵巢癌抗原抗体 |
| 别 名 | CA 125; CA125; CA-125; CA125 ovarian cancer antigen; Cancer antigen 125; FLJ14303; MUC16_HUMAN; MUC 16; MUC16; Mucin 16; MUC-16; Mucin 16 cell surface associated; Mucin16; Ovarian cancer related tumor marker CA125; Ovarian carcinoma antigen CA125; Ovarian cancer-related tumor marker CA125. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 肿瘤 信号转导 细胞类型标志物 细胞骨架 肿瘤细胞生物标志物 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, |
| 产品应用 | IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 200kDa |
| 细胞定位 | 细胞膜 |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CA125 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: MUC16 (CA125) is a serum marker that is used routinely in gynecologic practice to monitor patients with ovarian cancer. It is a mullerian duct differentiation antigen that is overexpressed in epithelial ovarian cancer cells and secreted into the blood, although its expression is not entirely confined to ovarian cancer. Most biochemical studies have concluded that MUC16 is a high molecular mass glycoprotein, although estimates of its size range from 200 to 2000 kDa with smaller “subunits” being described by some investigators. Function: Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. Subunit: Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Secreted, extracellular space. Note=May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain. Tissue Specificity: Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas. Post-translational modifications: Heavily O-glycosylated; expresses both type 1 and type 2 core glycans. Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans. May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space. May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts. Similarity: Contains 2 ANK repeats. Contains 56 SEA domains. Database links: Entrez Gene: 94025 Human SwissProt: Q8WXI7 Human Unigene: 432676 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. CA125是与卵巢癌细胞相关的膜表面糖蛋白。在正常情况下卵巢细胞中无CA125抗原，但在经期和孕期妇女的卵巢中发现存在由此种抗原。 该蛋白是上皮性卵巢癌尤其是浆液性腺癌的主要标记，也可用于其他恶性肿瘤的研究，如：乳腺癌、胰腺癌、肝癌和消化系统的肿瘤等。 |
